Retatrutide Shows Near‑Surgical Weight Loss in Phase 3 – Is It Realistic for Us?
Posted by rachel_ketogen in Weight Loss & Metabolic - 1 points, 0 comments.
The article reports Lilly’s Phase 3 TRIUMPH‑1 trial where participants on 12 mg retatrutide lost an average of 70 lb (28 %) over 80 weeks, with almost half hitting the 30 % mark that’s usually only seen after bariatric surgery. It also notes improvements in A1C, knee pain, and sleep apnea.
For me the numbers look impressive, but I’m skeptical about how well they’ll translate to everyday users. The trial cohort was likely highly selected, monitored closely, and had intensive lifestyle counseling – conditions we rarely get outside a study. Plus the 80‑week timeline is a long commitment; many of my clients drop off long before hitting those percentages. The side‑effect profile wasn’t covered in depth, and I’ve seen GLP‑1 agonists cause GI upset that can sabotage adherence.
Do you think the added GIP and glucagon activity will make retatrutide more tolerable than current GLP‑1s, or will we see the same drop‑out rates? 🤔
Community discussion - research and educational context only. Not medical advice.